Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living Europe.
Press releases published on May 12, 2025
Windtree Therapeutics Announces Presentation of Preclinical Data on Istaroxime and a Selective SERCA2a Activator at the European Society of Cardiology Heart Failure Conference May 17, 2025
GlobeNewswire
·
May 12, 2025
WARRINGTON, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …
Belite Bio to Participate in Four Upcoming Investor Conferences
GlobeNewswire
·
May 12, 2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical …
Best Weight Loss Supplements in USA 2025: Top Diet Pills That Actually Work Fast For Real Results - Wolfson Brands Ltd
GlobeNewswire
·
May 12, 2025
New York City, May 12, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Weight Loss Supplements …
SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction
GlobeNewswire
·
May 12, 2025
TEL AVIV, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central …
BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC
GlobeNewswire
·
May 12, 2025
PALO ALTO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire abstract and two moderated …
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
GlobeNewswire
·
May 12, 2025
BETHESDA, Md., May 12, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, …
Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress
GlobeNewswire
·
May 12, 2025
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a …
Optima Health plc - Full Year Trading Update
GlobeNewswire
·
May 12, 2025
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) …
Teva’s 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy
GlobeNewswire
·
May 12, 2025
The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva launched two new programs to help people around the world access the medicines they need, …
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
GlobeNewswire
·
May 12, 2025
Announced positive interim data for LX2006 from Phase 1/2 studies in Friederich ataxia (FA) cardiomyopathy; frataxin expression and LVMI improvement exceeded co-primary target thresholds for planned registrational study LX2006 registrational study expected …
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
GlobeNewswire
·
May 12, 2025
Mike Heffernan appointed as Chairman of the Board Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Cash on hand of approximately $125 million as of March 31, 2025 expected to provide runway …
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
GlobeNewswire
·
May 12, 2025
– Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway …
Harvard Bioscience Announces First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
HOLLISTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2025. Jim Green, Chairman and CEO, said, “First quarter revenues were in line …
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
GlobeNewswire
·
May 12, 2025
ZUG, Switzerland, May 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such …
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
GlobeNewswire
·
May 12, 2025
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Median …
Valneva fait un point sur les recommandations d’utilisation d'IXCHIQ® chez les personnes âgées aux États-Unis
GlobeNewswire
·
May 12, 2025
Saint Herblain (France), le 12 mai 2025 – Valneva SE (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que l’agence de santé américaine Food and Drug Administration (FDA) et les centres américains de …